Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Impel Pharmaceuticals Inc (IMPL)

Impel Pharmaceuticals Inc (IMPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 956
  • Shares Outstanding, K 23,900
  • Annual Sales, $ 12,650 K
  • Annual Income, $ -106,310 K
  • 60-Month Beta 1.17
  • Price/Sales 0.10
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IMPL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.13
  • Most Recent Earnings $-0.58 on 11/14/23
  • Latest Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.97
  • Growth Rate Est. (year over year) +103,089.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0212 +88.68%
on 12/20/23
1.0600 -96.23%
on 11/22/23
-0.2621 (-86.76%)
since 11/20/23
3-Month
0.0212 +88.68%
on 12/20/23
1.0600 -96.23%
on 11/22/23
-0.5010 (-92.61%)
since 09/20/23
52-Week
0.0212 +88.68%
on 12/20/23
4.2000 -99.05%
on 01/04/23
-3.1300 (-98.74%)
since 12/20/22

Most Recent Stories

More News
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 16.00 (-3.61%)
EVLO : 0.0495 (-1.00%)
FHTX : 5.30 (-4.16%)
MRNA : 101.41 (-0.58%)
OMGA : 2.40 (-0.83%)
SANA : 7.61 (-1.55%)
MCRB : 0.5599 (-4.16%)
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

IMPL : 0.0400 (-27.27%)
INFI : 0.0080 (-50.00%)
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 8.33% and 81.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

IPSC : 3.09 (+3.87%)
IMPL : 0.0400 (-27.27%)
Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ASRT : 0.7730 (+2.52%)
IMPL : 0.0400 (-27.27%)
Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 1.0800 (+2.86%)
IMPL : 0.0400 (-27.27%)
Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

OCUL : 5.22 (-10.92%)
IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

IMPL : 0.0400 (-27.27%)
VVOS : 2.72 (+2.26%)
ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PRPH : 5.26 (-3.31%)
IMPL : 0.0400 (-27.27%)
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

SAGE : 13.33 (+2.26%)
IMPL : 0.0400 (-27.27%)
FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 1.1500 (-1.71%)
IMPL : 0.0400 (-27.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.0817
2nd Resistance Point 0.0659
1st Resistance Point 0.0529
Last Price 0.0400
1st Support Level 0.0241
2nd Support Level 0.0083
3rd Support Level N/A

See More

52-Week High 4.2000
Fibonacci 61.8% 2.6037
Fibonacci 50% 2.1106
Fibonacci 38.2% 1.6175
Last Price 0.0400
52-Week Low 0.0212

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar